{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:42:47Z","timestamp":1793148167298,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,2,7]],"date-time":"2018-02-07T00:00:00Z","timestamp":1517961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.anai.2018.01.030","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T12:49:06Z","timestamp":1517489346000},"page":"504-511.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":103,"title":["Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma"],"prefix":"10.1016","volume":"120","author":[{"given":"Bradley E.","family":"Chipps","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Newbold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1232-9770","authenticated-orcid":false,"given":"Ian","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Trudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2018.01.030_bib0010","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/1471-2458-12-204","article-title":"Global asthma prevalence in adults: findings from the cross-sectional world health survey","volume":"12","author":"To","year":"2012","journal-title":"BMC Public Health"},{"key":"10.1016\/j.anai.2018.01.030_bib0015","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.anai.2018.01.030_bib0020","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1378\/chest.12-0412","article-title":"The poorly explored impact of uncontrolled asthma","volume":"143","author":"O'Byrne","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.anai.2018.01.030_bib0025","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1590\/S1806-37132014000400003","article-title":"Risk factors for death in patients with severe asthma","volume":"40","author":"Fernandes","year":"2014","journal-title":"J Bras Pneumol"},{"key":"10.1016\/j.anai.2018.01.030_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40733-016-0029-3","article-title":"Asthma costs and social impact","volume":"3","author":"Nunes","year":"2017","journal-title":"Asthma Res Pract"},{"key":"10.1016\/j.anai.2018.01.030_bib0035","author":"Global Initiative for Asthma"},{"key":"10.1016\/j.anai.2018.01.030_bib0040","author":"Genentech, Inc (South San Francisco, CA)"},{"key":"10.1016\/j.anai.2018.01.030_bib0045","author":"Genentech, Inc (South San Francisco, CA)"},{"key":"10.1016\/j.anai.2018.01.030_bib0050","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.01.030_bib0055","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1164\/ajrccm.155.6.9196083","article-title":"Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response","volume":"155","author":"Boulet","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.anai.2018.01.030_bib0060","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1067\/mai.2003.49","article-title":"Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma","volume":"111","author":"Corren","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.01.030_bib0065","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2018.01.030_bib0070","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.anai.2018.01.030_bib0075","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"suppl","key":"10.1016\/j.anai.2018.01.030_bib0080","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1513\/AnnalsATS.201306-168AW","article-title":"Eosinophilic phenotypes of airway disease","volume":"10","author":"Pavord","year":"2013","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.anai.2018.01.030_bib0085","first-page":"1","article-title":"Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice","volume":"9","author":"Price","year":"2016","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.anai.2018.01.030_bib0090","doi-asserted-by":"crossref","first-page":"e005748","DOI":"10.1136\/bmjopen-2014-005748","article-title":"Sputum eosinophilia is a determinant of FEV1 decline in occupational asthma: results of an observational study","volume":"5","author":"Talini","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.anai.2018.01.030_bib0095","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/JAA.S78049","article-title":"Benralizumab: a unique IL-5 inhibitor for severe asthma","volume":"9","author":"Tan","year":"2016","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.anai.2018.01.030_bib0100","first-page":"125","article-title":"The past, present, and future of monoclonal antibodies to IL-5 and eosinophilic asthma: a review","volume":"8","author":"Patterson","year":"2015","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.anai.2018.01.030_bib0110","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","article-title":"MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function","volume":"125","author":"Kolbeck","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.01.030_bib0115","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.rmed.2016.01.003","article-title":"Reductions in eosinophil biomarkers by benralizumab in patients with asthma","volume":"111","author":"Pham","year":"2016","journal-title":"Respir Med"},{"key":"10.1016\/j.anai.2018.01.030_bib0120","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.anai.2018.01.030_bib0125","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.anai.2018.01.030_bib0130","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1080\/03007995.2017.1347091","article-title":"The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies","volume":"33","author":"Goldman","year":"2017","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10.1016\/j.anai.2018.01.030_bib0135","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-2600(17)30344-2","article-title":"Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies [published online ahead of print September 8, 2017]","volume":"6","author":"FitzGerald","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.anai.2018.01.030_bib0140","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2018.01.030_bib0145","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/j.1365-2222.2011.03929.x","article-title":"Severe asthma: from characteristics to phenotypes to endotypes","volume":"42","author":"Wenzel","year":"2012","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.anai.2018.01.030_bib0150","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.anai.2015.10.027","article-title":"Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma","volume":"116","author":"Tran","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2018.01.030_bib0155","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.rmed.2004.10.008","article-title":"Measurement properties and interpretation of three shortened versions of the asthma control questionnaire","volume":"99","author":"Juniper","year":"2005","journal-title":"Respir Med"},{"key":"10.1016\/j.anai.2018.01.030_bib0160","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1477-7525-3-58","article-title":"Modification of the asthma quality of life questionnaire (standardised) for patients 12 years and older","volume":"3","author":"Juniper","year":"2005","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.anai.2018.01.030_bib0165","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/all.12914","article-title":"Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment","volume":"71","author":"Magnan","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2018.01.030_bib0170","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120618300619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120618300619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:18:56Z","timestamp":1761052736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120618300619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S1081120618300619"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2018.01.030","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2018.01.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}